Skip to main content

Arcturus Therapeutics Holdings Inc.

ARCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001768224

No open-market purchases or sales by Arcturus Therapeutics Holdings Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; ARK Invest is the only superinvestor holding it.

Q3 2022 vs. Q2 2022

How the institutions holding Arcturus Therapeutics Holdings Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ARCT: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders128117−11
Shares22.2M22.2M+13.5K (+0.1%)
Value$353.6M$328.1M−$25.5M (−7.2%)

New holders (14)

Institutions that held Arcturus Therapeutics Holdings Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ARCT in Q3 2022
InstitutionSharesValue% of portfolio
Woodline Partners LP877,524$13.0M0.19%
Acadian Asset Management LLC75,047$1.11M0.01%
ExodusPoint Capital Management, LP47,552$705.0K0.01%
Ameriprise Financial Inc14,020$208.0K0.00%
Susquehanna Fundamental Investments, LLC11,940$177.0K0.00%
Bayesian Capital Management, LP11,399$169.0K0.03%
Mirae Asset Global Investments Co., Ltd.10,212$152.0K0.00%
Lazard Asset Management LLC8,981$133.0K0.00%
Allspring Global Investments Holdings, LLC1,152$17.0K0.00%
Simplex Trading, LLC871$12.0K0.00%
China Universal Asset Management Co., Ltd.249$4.00K0.00%
Quadrant Capital Group LLC144$2.00K0.00%
Ameliora Wealth Management Ltd.150$2.00K0.00%
Wipfli Financial Advisors LLC,46$1.00K0.00%

Sold out (25)

Institutions that held Arcturus Therapeutics Holdings Inc. at the end of Q2 2022 and filed for Q3 2022 without it.